Korean Market
OWNR
ImmuneOncia Therapeutics
★

Outside Director PAIK SOONMYUNG acquires 8,544 shares via paid-in capital increase, raising stake to 0.05%... Limited impact on shareholder value

 
OWNR
ImmuneOncia Therapeutics
★

Yuhan's Stake in ImmuneOncia Drops from 67.37% to 57.23% After Rights Offering... Dilution Risk and Price Impact in Focus

 
OWNR
ImmuneOncia Therapeutics
★

Yuhan Corporation exercises warrants and oversubscribes in ImmuneOncia's rights offering, acquiring 2.74M new shares at KRW 4,860, ownership drops to 56.62% from 65.75%

 
ISSU
ImmuneOncia Therapeutics
★

81.8 Billion Won Rights Offering Completed, Issue Price 4,860 Won, Top Shareholder Stake Diluted to 56.62%

 
EXCH
ImmuneOncia Therapeutics
★

KRW 81.8 Billion Rights Offering Fully Subscribed, 16.8M New Shares to List on June 8

 
PERI
ImmuneOncia Therapeutics
★

ImmuneOncia Q1 2026: Operating Loss Continues, Capital Raise Decided

 
PERI
ImmuneOncia Therapeutics
★

ImmuneOncia: No Revenue, Expanding Operating Loss in Q1 2026, Rights Offering Decided

 
EXCH
ImmuneOncia Therapeutics
★★

Rights offering oversubscribed at 104.29%

 
ISSU
ImmuneOncia Therapeutics
★★

ImmuneOncia Rights Offering: Final Price at 4,860 Won, Raising ₩81.8B for IMC-001 Commercialization

 
ISSU
ImmuneOncia Therapeutics
★★

ImmuneOncia Finalizes 81.8 Billion Won Rights Offering at 4,860 Won for IMC-001 Commercialization

 
MATR
ImmuneOncia Therapeutics
★★

Rights Offering: 105.4B Won for Operations, Issue Price 4,860 Won

 
EXCH
ImmuneOncia Therapeutics
★★

Rights Offering Final Price Set at 4,860 Won

 
OWNR
ImmuneOncia Therapeutics
★

Submission of Report on Ownership of Specific Securities by Executives and Major Shareholders

 
OWNR
ImmuneOncia Therapeutics
★

Large Shareholding Report Filed (No Specifics)